Summary by Moomoo AI
Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
